Stopping a GLP-1: What the Research Says About Weight Regain and What to Track

Most conversations about GLP-1 medicines are about starting. Far fewer are about stopping, even though many people eventually do: the cost becomes too much, side effects wear them down, a goal weight is reached, or access to the supply changes. This guide covers what the research says about weight after stopping, and what is worth writing down so you are not guessing.

This is general information, not medical advice. How you come off any medicine is a decision for your prescriber, and nothing here is a dosing or tapering recommendation.

What the 2026 Cambridge review found

In March 2026, researchers at the University of Cambridge published a systematic review and model in eClinicalMedicine. They analysed 48 published studies of people who had lost weight on GLP-1 medicines and then stopped. The nonlinear model was fitted on six randomised trials with 3,236 participants in total.

The headline findings, as reported by the university and trade press:

• By 52 weeks after stopping, people had regained roughly 60 percent of the weight they lost on treatment.
• Extending the model beyond the data, the authors projected that regain slows and plateaus at around 75 percent of the weight lost.
• That still leaves some people keeping part of the loss, roughly a quarter on that projection.

How to read those numbers

A few caveats matter, and the authors and outside commentators raise them too.

• It is pooled data, not one long-term trial. The result combines many studies with different drugs, doses, populations and follow-up. It is an average.
• The 75 percent plateau is modelled. The trial data used to fit the model ran to 52 weeks after stopping. Anything past that is extrapolation.
• The analysis was limited to studies with meaningful weight loss on treatment, reported as at least 3 kg on average.
• An earlier preprint counted 44 studies; the published version reports 48. If you see slightly different numbers quoted online, that is probably why.
• Averages hide a wide range. Some people regain faster, some slower, and some hold most of the loss.

Treat it as a map of the typical pattern, not a forecast for you.

An earlier data point: the STEP 1 extension

Before the Cambridge review, the best-known evidence was the extension of the STEP 1 trial. Participants took semaglutide 2.4 mg or placebo for 68 weeks, then stopped. The authors reported that one year after withdrawal, participants had regained about two-thirds of their prior weight loss, and that improvements in several cardiometabolic markers moved back toward baseline. The extension analyses were exploratory, covered a subset of participants, and the trial was sponsored by the manufacturer. The authors concluded that obesity is a chronic condition and that ongoing treatment is likely needed to keep the benefits.

That is broadly consistent with the Cambridge estimate, which is reassuring about the overall picture and not a reason for blame. Regain after stopping is a documented biological pattern, not a personal failing.

Why people stop

Knowing your own reason helps you plan the exit with your clinician rather than drift out of treatment.

Reason	What it often looks like	What to log
Cost	Price rise, insurance change, coverage lapse	Monthly spend, what changed, alternatives discussed
Side effects	Persistent nausea, fatigue, GI trouble	Symptom, severity, timing, what helped
Goal reached	Target weight or health marker hit	The target, and what the plan is to hold it
Access	Shortage, supplier change, travel, pharmacy issues	Gaps between supplies, dates missed
Life events	Pregnancy planning, surgery, illness	Clinician guidance given

Stopping because of a shortage or a billing problem is very different from a planned stop, and the log should say which one it was. If side effects are the reason, see our side-effect tracking guide before you decide; sometimes the better conversation is about managing them.

Stopping is the prescriber's call

Whether you stop abruptly, step down, switch to another medicine or pause is a clinical decision. It depends on your dose, your history, your other conditions and why you are stopping. TrackPep does not publish tapering schedules and neither should a blog post. What we can do is help you arrive at the appointment with something better than memory.

Questions worth asking your prescriber before you stop:

• Is stopping outright reasonable for me, or is there a step-down or switch worth considering?
• What should I expect in the first weeks: appetite, weight, blood sugar?
• Which of my other medicines or conditions are affected by the change?
• What number or symptom should make me call you?
• If I need to restart, how would that work and how fast could it happen?

What to log after you stop

The goal is a simple, low-effort record that shows a trend early. Do not try to track everything; pick the handful that you will actually keep up.

1. Weekly weight trend

Daily weight is noisy. Weigh at the same time under similar conditions, then look at the weekly average rather than any single reading. Our guide to tracking weight on GLP-1 explains the noise problem. After stopping, the weekly average is the number to watch, because it reveals direction before a single scary morning does.

2. Appetite and hunger

Rate hunger and fullness once a day or a few times a week on a 1 to 5 scale. Appetite changes are often the first thing people notice, and they usually arrive before the scale moves.

3. Food noise notes

If you experienced less intrusive thinking about food on treatment, note when it returns. A short free-text line works: "afternoon cravings back, evening snacking." This is subjective, and that is fine. The pattern over weeks is what matters.

4. Protein

Protein intake supports satiety and lean mass. Our post on how much protein on a GLP-1 covers public guidance. After stopping, log whether you are hitting your usual intake, since appetite changes can nudge it around without you noticing.

5. Strength training

Keeping resistance training going is one of the more controllable habits. See the muscle preservation 3-day plan for a plain template. Log sessions per week, not perfection.

6. Steps and general activity

A daily step count is passive and easy to keep. A drop in activity often shows up alongside weight drift.

7. Sleep

Short or broken sleep tends to raise hunger. A rough hours-per-night entry is enough.

8. Waist

Measure the waist every two to four weeks at the same landmark. Waist can tell a different story from the scale, especially if you are strength training.

Quick checklist

• Weekly average weight
• Hunger and fullness rating
• One line on food noise
• Protein roughly on target
• Strength sessions this week
• Average steps
• Sleep hours
• Waist every few weeks
• Any cost or access change

Early-warning thresholds: agree them in advance

One of the most useful things you can do is decide, with your clinician, what counts as a signal before you are in the middle of it. Do not borrow a number from the internet. Instead, have a conversation like this:

• "If my weekly average rises by more than a figure we choose together across a set number of weeks, I will message you."
• "If hunger ratings stay high for a period we agree on, we will review the plan."
• "If my waist or blood pressure or glucose readings move beyond what we set, we will meet."

Write the agreed rule into your notes so it is visible when you review your data. The point is not to panic at each fluctuation but to make a pre-agreed decision rather than an emotional one. Your clinician may choose a different threshold from anyone else's, and that is correct.

Questions for a maintenance plan

Whether or not you stay off medicine, having a plan to hold your weight is worth discussing:

• What will my maintenance calorie and protein range look like, and who helps me set it?
• What activity routine am I committing to, and how will I measure it?
• Which health markers should be rechecked, and when?
• If weight returns, what are the options: restart, switch, add support, or something else?
• Is there a dietitian, coach or programme I can use?
• What does follow-up look like in months one, three and six?

Log the money and the access too

Cost and supply are often the actual reason treatment ends, and they are rarely tracked. Keep a simple record of:

• Monthly spend before and after the change.
• Dates of any gaps between supplies.
• What the provider, pharmacy or insurer told you, and when.
• Alternatives you considered.

If you cannot afford to continue, a clean record helps you ask your clinician about other options and helps you spot a pattern if gaps repeat. Our posts on GLP-1 costs in 2026 and tracking cost per dose can help.

Putting it together in TrackPep

If you already log your GLP-1 in TrackPep, you can keep the same history going after your last dose: weight entries, notes, measurements and the date things changed. The GLP-1 tracker, semaglutide tracker and tirzepatide tracker pages explain what you can record. TrackPep records what you enter and shows it back to you. It does not recommend a dose, a taper or a supplier, and it cannot tell you when to stop.

Bottom line

The research is consistent in direction: on average, a lot of weight returns after stopping, most of it in the first year. The exact percentages are pooled and modelled, so hold them lightly. What you can control is the quality of your information. A weekly trend, a few honest notes and a pre-agreed plan with your prescriber turn stopping from a cliff into something you can see coming.